Items tagged with Diagnostics
Xpert Xpress SARS-CoV-2 cartridge now available from Stop TB Partnership’s Global Drug Facility (post)
27 March 2020, Geneva, Switzerland – The Stop TB Partnership’s Global Drug Facility (GDF) has expanded its Diagnostics Catalog to include a new test for novel coronavirus SARS-CoV-2, the virus that causes COVID-19 disease. The Xpert Xpress SARS-CoV-2 test cartridges are now available at US$19.80 per cartridge from the manufacturer, Cepheid. For the full listing, see the GDF Diagnostics Catalog.
Webinar recording: Fair pricing for Cepheid Xpert tests (COVID-19, HIV, TB, HCV) (post)
On 3 April 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, HIV, TB, HCV and other diseases. The webinar provided the latest information about the “Time for $5” campaign and the evidence base for why GeneXpert tests should be priced at US$5.
WHO launches online course to improve diagnosis of drug-resistant TB (post)
WHO/Europe has launched a new online course to strengthen the capacity to diagnose drug-resistant tuberculosis (DR-TB) using molecular techniques. This free course, entitled “Drug-resistant tuberculosis: how to interpret rapid molecular test results”, is available on the OpenWHO platform and includes opportunities for participants throughout the world to seek expert advice for their diagnostic questions.
Newly available tests for rapid TB diagnosis: what you need to know (post)
15 May 2020, Geneva, Switzerland – Three products have recently been made available to support TB programmes’ efforts to reach UN TB targets to detect and treat 40 million people with TB by 2022, including 3.5 million children, as well as 1.5 million people with drug-resistant TB. All three tests offer opportunities for multiplexing, with menus of tests for other diseases available, including COVID-19 tests.
Review finds test antibiotics unreliable for diagnosing TB (post)
May 20, 2020 -- New research by scientists from the United Kingdom and Africa suggests a long-standing practice of using antibiotics to test whether an individual may have tuberculosis (TB) is an unreliable method for diagnosing the disease.
New multi-functional TB blood test validated (post)
Researchers from the South African Tuberculosis Vaccine Initiative (SATVI) at the University of Cape Town (UCT), the Center for Global Infectious Disease Research – Seattle in the United States, and a large consortium of collaborators have developed a validated a new, simple blood-based test that has the potential to serve multiple functions in the fight against TB.
The Stop TB Partnership’s Global Drug Facility to distribute 100,000 Xpert® Xpress SARS-CoV-2 tests for COVID-19 (post)
10 June 2020, Geneva, Switzerland - The Stop TB Partnership today announced that its Global Drug Facility (GDF) will distribute 100,000 Xpert® Xpress SARS-CoV-2 tests donated by Cepheid towards the fight against the COVID-19 pandemic. Xpert® Xpress SARSCoV-2 is a rapid molecular diagnostic test for the qualitative detection of SARS-CoV-2, the virus causing COVID-19. The test has been designed to operate on any of the more than 23,000 GeneXpert® Systems worldwide, with a detection time of approximately 45 minutes.
Update of the WHO guidance on screening for active TB (post)
The World Health Organization (WHO) is convening a Guideline Development Group (GDG) to advise on updates needed to its recommendations on the systematic screening for tuberculosis (TB).
Public call for data on diagnostic accuracy of nucleic acid amplification tests to detect TB and DR-TB (post)
18 June 2020, Geneva | Nucleic acid amplification tests (NAAT) are promising technologies for the rapid and accurate detection of TB and resistance to selected anti-TB agents. In December 2020, the World Health Organization (WHO) will convene a Guidelines Development Group (GDG) meeting to update its diagnostic guidelines on the use of NAATs to detect TB and resistance to selected anti-TB agents. Ahead of this meeting, WHO will commission reviews of relevant evidence on diagnostic accuracy for several NAAT assays.
Webinar: From Policy to Practice: Rolling out new WHO guidelines on rapid diagnostics and drug-resistant TB treatment (post)
The World Health Organization (WHO) will host a webinar on 9 July 2020 to provide key updates on recently released new WHO guidance on rapid diagnostics and drug-resistant TB treatment.
Page 38 of 67 · Total posts: 0
←First 37 38 39 Last→